<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>InSpiro &#187; Йоана Милушева</title>
	<atom:link href="http://inspiro-bg.com/author/yoana_milusheva/feed/" rel="self" type="application/rss+xml" />
	<link>https://inspiro-bg.com</link>
	<description>Списание за респираторна медицина и вдъхновение</description>
	<lastBuildDate>Fri, 23 Oct 2026 08:08:08 +0000</lastBuildDate>
	<language>en</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.2.1</generator>
		<item>
		<title>Саркопенията като прогностичен и предиктивен фактор при пациенти с метастатичен NSCLC, получаващи втора линия имунотерапия с PEMBROLIZUMAB</title>
		<link>https://inspiro-bg.com/sarkopeniyata-kato-prognostitchen-i-prediktiven-faktor-pri-patsienti-s-metastatitchen-nsclc-polutchavashti-vtora-liniya-imunoterapiya-s-pembrolizumab/</link>
		<comments>https://inspiro-bg.com/sarkopeniyata-kato-prognostitchen-i-prediktiven-faktor-pri-patsienti-s-metastatitchen-nsclc-polutchavashti-vtora-liniya-imunoterapiya-s-pembrolizumab/#comments</comments>
		<pubDate>Fri, 04 Nov 2022 09:05:04 +0000</pubDate>
		<dc:creator>Йоана Милушева</dc:creator>
				<category><![CDATA[2022]]></category>
		<category><![CDATA[Акцент на началната страница]]></category>
		<category><![CDATA[Архив]]></category>
		<category><![CDATA[Брой № 3 (66) / юни 2022]]></category>
		<category><![CDATA[Рубрики]]></category>

		<guid isPermaLink="false">http://inspiro-bg.com/?p=16093</guid>
		<description><![CDATA[Използвани съкращения КТ &#8211; компютърна томография ХТ &#8211; химиотерапия ЯМР &#8211; ядрено магнитен резонанс ASM &#8211; appendicular skeletal muscle mass AUC &#8211; area under the curve BMI &#8211; body mass index CBR &#8211; clinical benefit rate CI &#8211; confidential interval ECOG PS &#8211; Eastern Cooperative Oncology Group Performance Status EGFR &#8211; epidermal growth factor receptor]]></description>
		<wfw:commentRss>https://inspiro-bg.com/sarkopeniyata-kato-prognostitchen-i-prediktiven-faktor-pri-patsienti-s-metastatitchen-nsclc-polutchavashti-vtora-liniya-imunoterapiya-s-pembrolizumab/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
